Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.34 |
| ▸ | GABRR1 | P24046 | 4/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.34 |
| ▸ | GABRA4 | P48169 | 4/20 | 0.34 |
| ▸ | SLC6A12 | P48065 | 4/20 | 0.34 |
| ▸ | SLC6A13 | Q9NSD5 | 4/20 | 0.34 |
| ▸ | SLC6A11 | P48066 | 3/20 | 0.32 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8819835 | 0.81 | GABRA1 (0.33) | GABRA1GABRR1GABRA5GABRB2GABRA4 | |
| SCHEMBL3751940 | 0.74 | — | — | |
| SCHEMBL9166499 | 0.70 | — | — | |
| SCHEMBL746463 | 0.68 | — | — | |
| SCHEMBL31427048 | 0.68 | SLC6A12 (0.34) | GABRA1GABRR1GABRA5GABRB2GABRA4 | |
| SCHEMBL9334066 | 0.67 | — | — | |
| SCHEMBL9829487 | 0.65 | — | — | |
| SCHEMBL7422533 | 0.64 | TDP1 (0.31) | — | |
| SCHEMBL10556453 | 0.64 | — | — | |
| SCHEMBL1101334 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0251194-B1 | USE OF CARBOCYCLIC AND HETEROCYCLIC CONDENSED DIHYDROPYRIDINES FOR THE PREPARATION OF CARDIOPROTECTIVE REMEDIES AND HETEROCYCLIC AND CARBOCYCLIC CONDENSED DIHYDROPYRIDINES AND METHODS AND INTERMEDIATES FOR THEIR PREPARATION | BOEHRINGER INGELHEIM KG (DE) | 1993-03-31 | — | — | EP | claimed |
| US-20080214646-A1 | Novel Nsaids Possessing a Nitric Oxide Donor Diazen-1-Ium-1,2-Diolate Moiety | UNIVERSITY OF ALBERTA (CA) | 2008-09-04 | — | — | US | disclosed |
| EP-1885375-A1 | NOVEL NSAIDS POSSESSING A NITRIC OXIDE DONOR DIAZEN-1-IUM-1,2-DIOLATE MOIETY | The Governors of the University of Alberta (CA) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006125016-A1 | NOVEL NSAIDS POSSESSING A NITRIC OXIDE DONOR DIAZEN-1-IUM-1,2-DIOLATE MOIETY | THE GOVERNORS OF THE UNIVERISITY OF ALBERTA (CA) | 2006-11-23 | — | — | WO | disclosed |
| WO-1997046207-A2 | AROMATIC HETEROCYCLIC DERIVATIVES AS ENZYME INHIBITORS | CORVAS INTERNATIONAL, INC. (US) | 1997-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214646-A1 | Novel Nsaids Possessing a Nitric Oxide Donor Diazen-1-Ium-1,2-Diolate Moiety | PTGS1, NOS1, NOS2 | GABRA1 970/4885GABRR1 1058/4885GABRA5 2011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.